Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy MacroGenics stock | $19.05

Learn how to easily invest in MacroGenics stock.

MacroGenics Inc is a biotechnology business based in the US. MacroGenics shares (MGNX) are listed on the NASDAQ and all prices are listed in US Dollars. MacroGenics employs 370 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in MacroGenics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MGNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MacroGenics stock price (NASDAQ: MGNX)

Use our graph to track the performance of MGNX stocks over time.

MacroGenics shares at a glance

Information last updated 2021-10-23.
Latest market close$19.05
52-week range$18.16 - $36.48
50-day moving average $21.38
200-day moving average $25.86
Wall St. target price$36.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.27

Buy MacroGenics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MacroGenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MacroGenics price performance over time

Historical closes compared with the close of $19.05 from 2021-10-26

1 week (2021-10-21) -1.96%
1 month (2021-09-28) -7.61%
3 months (2021-07-28) -27.87%
6 months (2021-04-28) -46.02%
1 year (2020-10-27) -10.56%
2 years (2019-10-25) 118.71%
3 years (2018-10-26) 9.36%
5 years (2016-10-27) 23.85

Is MacroGenics under- or over-valued?

Valuing MacroGenics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MacroGenics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MacroGenics's PEG ratio

MacroGenics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MacroGenics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

MacroGenics financials

Revenue TTM $118.6 million
Gross profit TTM $-88,318,000
Return on assets TTM -21.55%
Return on equity TTM -45.63%
Profit margin -109.07%
Book value $5.31
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting MacroGenics shares

There are currently 3.2 million MacroGenics shares held short by investors – that's known as MacroGenics's "short interest". This figure is 1.1% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting MacroGenics shares can be evaluated.

MacroGenics's "short interest ratio" (SIR)

MacroGenics's "short interest ratio" (SIR) is the quantity of MacroGenics shares currently shorted divided by the average quantity of MacroGenics shares traded daily (recently around 1.0 million). MacroGenics's SIR currently stands at 3.08. In other words for every 100,000 MacroGenics shares traded daily on the market, roughly 3080 shares are currently held short.

However MacroGenics's short interest can also be evaluated against the total number of MacroGenics shares, or, against the total number of tradable MacroGenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MacroGenics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 MacroGenics shares in existence, roughly 50 shares are currently held short) or 0.054% of the tradable shares (for every 100,000 tradable MacroGenics shares, roughly 54 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MacroGenics.

Find out more about how you can short MacroGenics stock.

MacroGenics share dividends

We're not expecting MacroGenics to pay a dividend over the next 12 months.

MacroGenics share price volatility

Over the last 12 months, MacroGenics's shares have ranged in value from as little as $18.16 up to $36.48. A popular way to gauge a stock's volatility is its "beta".

MGNX.US volatility(beta: 2.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MacroGenics's is 2.2058. This would suggest that MacroGenics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

MacroGenics overview

MacroGenics, Inc. , a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.

Frequently asked questions

What percentage of MacroGenics is owned by insiders or institutions?
Currently 2.564% of MacroGenics shares are held by insiders and 95.566% by institutions.
How many people work for MacroGenics?
Latest data suggests 370 work at MacroGenics.
When does the fiscal year end for MacroGenics?
MacroGenics's fiscal year ends in December.
Where is MacroGenics based?
MacroGenics's address is: 9704 Medical Center Drive, Rockville, MD, United States, 20850
What is MacroGenics's ISIN number?
MacroGenics's international securities identification number is: US5560991094
What is MacroGenics's CUSIP number?
MacroGenics's Committee on Uniform Securities Identification Procedures number is: 556099109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site